Piramal Pharma Share Price Target Forecasts 2025 to 2030

Piramal Pharma Share Price Target : Are you thinking of investing in tcs shares? Want to know its future Price target? In this guide, we will discuss Piramal pharma share price target for the year 2025, 2026, 2030. Along with this, we will do a complete fundamental analysis to help you make the right decision.

OUR BUSINESS

Our Company was incorporated on March 4, 2020 in Mumbai, Maharashtra We are a Pharmaceutical company with global operations, providing end-to-end pharma services to customers and a portfolio of differentiated pharma products across a domestic and global distribution network.

We operate under three business verticals :

• Piramal Pharma Solutions (“PPS”), an integrated contract development and manufacturing organization (“CDMO”).
• Piramal Critical Care (“PCC”), a complex hospital generics (“CHG”) Business.
• India consumer healthcare (“ICH”) business, selling over-the-counter (“OTC”) Products.

CDMO business :

Our CDMO provides integrated drug discovery, development, and manufacturing services for both drug substances i.e. active
pharmaceutical ingredients (“APIs”) and drug products i.e. formulations across lifecycle of a molecule from discovery and
clinical development to commercial launch.

Presently, it has a diverse customer base of over 500 customers comprising global innovator pharma companies, emerging biopharma companies and generic pharma companies.

Our integrated network of facilities for the CDMO operations are located across India, UK and North America and we have
obtained and maintain requisite approvals from various global regulatory agencies.

We have development and manufacturing capabilities in areas such as high potency APIs, antibody drug conjugates (“ADC”), peptides, sterile injectables and hormonal Products.

CHG business :

Our CHG portfolio comprise of over 35 hospital-focused products in the areas of inhalation anaesthesia, injectable anaesthesia,
pain management, intrathecal therapy and other injectables.

We are the fourth largest company globally as per USD value for a combined market of Sevoflurane, Desflurane, Isoflurane and Halothane.

We are vertically integrated in inhalation anaesthesia. We manufacture both API and drug products at the Digwal, India and Bethlehem, US facilities as well as the key starting material at the Dahej, India facility.

ICH business :

Our ICH business has a diverse portfolio of over 30 OTC products across categories of analgesics, skin care, VMS, kids’ wellness, digestives, women’s health, and hygiene and protection categories, with well-known brands such as Little’s, Lacto Calamine, I-Pill, Polycrol, and Tetmosol.

We sell our products to several stockists that has reach across chemist and cosmetics stores, kids’ toys and gift shops, and modern trade stores. We have also launched our own e-commerce website, wellify.in.

we have 17 development and manufacturing facilities across India, North America and UK with atrack record having cleared periodic regulatory inspections in various jurisdictions.

our facilities at Ahmedabad PDS, Ahmedabad PPDS, Ennore and Rabale have been recognised by the Department of Scientific and Industrial Research.

Our diversified manufacturing footprint enables market proximity for customers and a cost efficient production cycle. We also have
a global distribution network in over 100 countries as of December 31, 2022.

• Our 17 development and manufacturing facilities across the globe with ten in India and seven outside India.
• Distribute our products in over 100 countries.
• 6,219 full-time employees across the world with 4,618 in India and 1,601 outside India.
• Have 21 subsidiaries with 20 of suchSubsidiaries incorporated outside India in, among others, South Africa, Japan, Italy, UK, Canada, Australia and US.

Piramal Pharma Fundamentals

Also Read : GRSE Share Price Target Forecasts 2025 to 2030

Piramal Pharma Shareholding Pattern

Piramal Pharma Financial Reports

Piramal Pharma Share Price Target 2025

The share price of Piramal Pharma may Ups & Down. According to our analysis levels, the minimum price of Piramal Pharma share in 2025 can be ₹198 and the maximum price can be ₹350.

Also Read : IRFC Share Price Target Forecasts 2025 to 2030

Piramal Pharma Share Price Target 2026

The share price of Piramal Pharma may Ups & Down. According to our analysis levels, the minimum price of Piramal Pharma share in 2026 can be ₹325 and the maximum price can be ₹600.

Also Read : Mazagon Dock Shipbuilders Share Price Target 2025 to 2030

Piramal Pharma Share Price Target 2027

The share price of Piramal Pharma may Ups & Down. According to our analysis levels, the minimum price of Piramal Pharma share in 2027 can be ₹550 and the maximum price can be ₹900.

Also Read : IREDA Share Price Target & Forecast 2025–2030

Piramal Pharma Share Price Target 2028

The share price of Piramal Pharma may Ups & Down. According to our analysis levels, the minimum price of Piramal Pharma share in 2028 can be ₹800 and the maximum price can be ₹1450.

Also Read : NTPC Share Price Target Forecasts 2025 to 2030

Piramal Pharma Share Price Target 2029

The share price of Piramal Pharma may Ups & Down. According to our analysis levels, the minimum price of Piramal Pharma share in 2029 can be ₹1500 and the maximum price can be ₹2100.

Piramal Pharma Share Price Target 2030

The share price of Piramal Pharma may Ups & Down. According to our analysis levels, the minimum price of Piramal Pharma share in 2030 can be ₹1950 and the maximum price can be ₹2700.

To buy Piramal pharma you can easily buy shares of Piramal pharma by using the trading platform of many stock brokers.

The names of most trading platforms for buying Piramal pharma shares are given below :

• Groww App
• Phonepe. Share Market App
• Angel One App
• Dhan App
• Upstox App
• Zerodha App

Frequently Asked Questions on Piramal pharma Share Price Target

Question 1: What is the share price target of Piramal pharma for 2025?

Answer 1: The estimated share price target for 2025 can range from ₹198 to ₹350.

Question 2: What is the share price target of Piramal pharma for 2030?

Answer 2: The estimated share price target of Piramal pharma for 2030 can range from ₹1950 to ₹2700.

Question 3: What are the primary growth drivers for tcs stock?

Answer 3: The most prominent growth drivers include a diversified portfolio, strategic market expansion, technological innovations, strong brand loyalty, etc.

Question 4: Is Piramal pharma a good long-term investment?

Answer 4: Yes,Piramal pharma shows a strong long-term potential due to its diversified operations, strategic expansion along with focus on further sustainability Investors should keep an eye on the company’s Q3 results to stay updated on market trends and company performance.

Disclaimer :- The above article is for informational purposes only, and should not be construed as any investment advice. Money Mint idea suggests its readers/viewers to consult their financial advisors before making any money-related decisions.